CVRx, a commercial-stage medical device company, reported strong financial results for Q4 and full year 2025, with revenue growth exceeding expectations.
The transition to Category I CPT codes and FDA approval for the BENEFIT-HF trial design highlight key milestones achieved.
The Company's debt facility amendment and revenue projections for fiscal 2026 demonstrate strategic growth initiatives.
Revenue Growth
Q4 2025 revenue expected to be $15.9-16.1M, FY 2025 revenue projected at $56.5-56.7M, with an outlook of $63-67M for 2026.
Strategic Milestones
Achieved Category I CPT codes adoption, FDA approval for BENEFIT-HF trial, and debt facility amendment.
Operational Expansion
Increased active implanting centers, sales territories, and cash reserves in 2025.
- CVRx's revenue growth in Q4 2025 and the full year showcases the company's market traction and positive financial performance.
- FDA approval for the BENEFIT-HF trial design and the debt facility amendment signal forward momentum and strategic advancements.
- The Company's business outlook for 2026 positions it for continued expansion and innovation in the cardiovascular healthcare sector.
With a strong financial performance in 2025 and strategic initiatives set for 2026, CVRx is poised for growth and market leadership in the cardiovascular medical device industry.